Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for thyroid cancer.

P J Hoskin1, C Harmer

  • 1Thyroid Unit, Royal Marsden Hospital, Sutton, Surrey, U.K.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When to Hold and When to Fold: The Clinical Approach to Locoregional Recurrence After Curative Treatment of Solid Cancers.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Technical Aspects of a National Service for Paediatric Pelvic Brachytherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

The Use of Artificial Intelligence Technologies in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Urinary biomarkers in metastatic bone pain: Results from a multicentre randomized trial of ibandronate compared to single dose radiotherapy for localized metastatic bone pain in prostate cancer (RIB).

Journal of bone oncology·2024
Same author

Functional Magnetic Resonance Imaging in Cervical Cancer Diagnosis and Treatment.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Promoting Early Radiation Research Exposure Through the Royal College of Radiologists' Summer Undergraduate Research Fellowship.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Dosimetric verification of every treatment plan: Do or not to do?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives? Optimizing PSQA in radiotherapy workflows through commissioning and standardized treatment planning with class solutions.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
See all related articles

Sequential chemotherapy, including etoposide and cis-platinum, shows activity in advanced thyroid cancer. Some patients experienced improved survival and symptom control with these treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced thyroid cancer often presents challenges in treatment, necessitating exploration of novel therapeutic strategies.
  • Chemotherapy plays a role in managing progressive, symptomatic, or metastatic thyroid cancer unresponsive to conventional therapies.

Observation:

  • Twenty-nine patients with advanced thyroid cancer received sequential chemotherapy with single agents (etoposide, carboplatin, cis-platinum, methotrexate) or the adriamycin, bleomycin, and vincristine (ABC) combination.
  • Response rates varied across agents: etoposide (4/22), carboplatin (2/9), cis-platinum (5/13), methotrexate (1/3), and ABC (5/13).

Findings:

  • Etoposide, carboplatin, and cis-platinum demonstrated activity as single agents in thyroid carcinoma.
  • A single complete response was observed with etoposide.

Related Experiment Videos

  • Patients under 65 and those with medullary carcinoma exhibited higher response rates.
  • Mean survival was 11.9 months, with responders living significantly longer (19 months) than non-responders (5.4 months).

    • Implications:

    • Sequential chemotherapy regimens can offer viable treatment options for advanced thyroid cancer.
    • Etoposide, carboplatin, and cis-platinum are active agents that may improve symptom control and survival in select patients.
    • Further research into optimal sequencing and patient selection for chemotherapy in thyroid cancer is warranted.